See also this year's filing and all EDGAR filings for this company.
PDF Report 0001114220_2016_Keryx_Biopharmaceuticals_INC.pdf
Logs
| warning | The EntityCommonStockSharesOutstanding does not exist | industry.us_generic | {} |
| warning | Similarly named company. Duplicate? | None | {'details': [{'other_company': 'Regenerx Biopharmaceuticals INC', 'shared_tokens': {'biopharmaceuticals'}}]} |
| warning | Missing logo | subcommand.report | {} |
Graph
Absolute values for 0001114220, Keryx Biopharmaceuticals INC
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 249,294,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 3,208,000 |
| 2 | PropertyPlantAndEquipmentNet | 5,083,000 |
| 3 | remainder_Assets | 1,100,000 |
| 4 | LiabilitiesCurrent | 77,606,000 |
| 5 | LiabilitiesNoncurrent | 1,076,000 |
| 6 | remainder_Liabilities | 93,069,000 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 90,108,755 |
| 9 | ResearchAndDevelopmentExpense | 38,173,491 |
| 10 | remainder_Expenses | 34,428,999 |
| 11 | remainder_Revenues | 5,126 |
| 12 | remainder_NetIncome | 11,220,933 |
| 13 | remainder_ComprehensiveNetIncome | 0 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 258,685,000 |
| 1 | Liabilities | 171,751,000 |
| 2 | Expenses | 162,711,245 |
| 3 | Revenues | 5,126 |
| 4 | StockholdersEquity | 86,934,000 |
| 5 | NetIncome | -151,485,186 |
| 6 | ComprehensiveNetIncome | -151,485,186 |
| 7 | BaseVar | 302,186,652 |
| 8 | EconomicCapitalRatiobeforeLimitedLiability | 0.177 |
| 9 | EconomicCapitalRatio | 1.58 |
Edgar->Model Mapping
Feature Distribution
Change over Time
